PDCD1 and non-small cell lung carcinoma: Similarly, in the more recent randomized, phase III EMPOWER-Lung 1 trial, which evaluated the PD-1 inhibitor cemiplimab versus platinum-based chemotherapy in untreated, advanced NSCLC with PD-L1 expression greater than or equal to 50%, increasing PD-L1 expression levels (50%–60%, 61%–89%, and ≥90%) were found to correlate with incremental improvements in ORR, PFS, and OS.4